for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.AS

Latest Trade

46.40EUR

Change

-0.34(-0.73%)

Volume

104,052

Today's Range

46.00

 - 

46.86

52 Week Range

45.30

 - 

127.70

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
46.74
Open
46.69
Volume
104,052
3M AVG Volume
8.74
Today's High
46.86
Today's Low
46.00
52 Week High
127.70
52 Week Low
45.30
Shares Out (MIL)
65.52
Market Cap (MIL)
2,983.59
Forward P/E
-14.71
Dividend (Yield %)
--

Next Event

Q3 2021 Galapagos NV Earnings Release

Latest Developments

更多

Galapagos Announces Positive CHMP Opinion For Jyseleca (Filgotinib)

Galapagos Announces Planned Retirement Of CEO

Galapagos H1 Net Loss Narrows To 55 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Industry

Biotechnology & Drugs

Contact Info

Generaal De Wittelaan 3

2800

Belgium

+32.15.342900

http://www.glpg.com

Executive Leadership

Onno van de Stolpe

Chairman of the Executive Committee, Chief Executive Officer

Rajesh B. Parekh

Non-Executive Chairman of the Board

Bart Filius

President, Chief Financial Officer, Chief Operating Officer, Member of the Executive Board

Piet Wigerinck

Member of the Executive Committee, Chief Scientific Officer

Walid Abi-Saab

Member of the Executive Committee, Chief Medical Officer

Key Stats

3.15 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.3K

2019

0.9K

2020

0.5K

2021(E)

0.5K
EPS (EUR)

2018

-0.560

2019

2.490

2020

-4.690

2021(E)

-3.096
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.12
Price To Book (MRQ)
1.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.05
LT Debt To Equity (MRQ)
0.80
Return on Investment (TTM)
-4.41
Return on Equity (TTM)
-3.94

Latest News

Latest News

UPDATE 1-Galapagos and Gilead to end late-stage studies of lung disease drug

Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis, the companies said on Wednesday.

Galapagos and Gilead discontinue studies of lung disease drug

Galapagos NV and partner Gilead Sciences Inc will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis, the companies said on Wednesday.

UPDATE 1-Gilead says not to pursue U.S. approval for rheumatoid arthritis drug

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval for its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

UPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients. Filgotinib is also in advanced stages of testing...

Gilead-Galapagos's drug meets main goals of ulcerative colitis study

Gilead Sciences Inc and partner Galapagos NV said on Wednesday a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a mid-stage study testing it in ulcerative colitis patients.

BRIEF-Galapagos Q1 Net Loss Widens To 50.6 Million Euros

* ANNOUNCED ON THURSDAY : FIRST THREE-MONTH 2020 FINANCIAL RESULTS

BRIEF-Galapagos Announces Share Capital Increase Through Warrant Exercises For EUR 2.7 Mln

* SAID ON MONDAY ISSUED 95,180 NEW ORDINARY SHARES ON NOV 25, FOR TOTAL CAPITAL INCREASE OF EUR 2.7 MLN

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN

CORRECTED-BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS

UPDATE 4-Gilead invests $5 bln to deepen ties with biotech Galapagos

* Gilead makes $3.95 bln upfront payment, $1.1 equity investment

Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report

Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

BRIEF-Galapagos FY Revenue Up At 317.8 Million Euros

* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up